Novavax has raised its 2026 revenue outlook by $145m at the midpoint, to between $385m and $415m, after earning a $125m milestone from Sanofi in October. Third-quarter revenue slipped 3% to $68.3m, but cost cuts helped narrow the net loss to $31.4m from $202.4m a year earlier.
The Sanofi milestone
The jump in guidance comes almost entirely from the milestone. On 29 October Novavax said Sanofi had dosed the fifth patient in a Phase 3 trial in Europe of a combined flu and Covid vaccine, triggering a $125m payment. The trial tests Novavax's Covid vaccine, Nuvaxovid, given together with Sanofi's high-dose flu vaccine, Efluelda/Fluzone High-Dose, in adults aged 60 and over.
Novavax says the partnership with Sanofi, signed in May 2024, has now brought in more than $1bn, counting upfront payments, milestones, research reimbursements and royalties. Two more milestones are in sight: $75m when the transfer of Nuvaxovid manufacturing technology to Sanofi is completed, expected in mid-2027, and $225m if a combined flu and Covid vaccine is launched in the US. Sanofi intends to start a US Phase 3 trial of the combination in 2027.
Novavax: share price, chart and news

The third quarter
| Measure | Q3 2026 | Q3 2025 |
|---|---|---|
| Total revenue | $68.3m | $70.4m |
| Product sales | $25.7m | $13.4m |
| Licensing, royalties and other | $42.6m | $57.0m |
| Research and development | $52.4m | $98.3m |
| Selling, general and administrative | $23.6m | $31.7m |
| Net loss | $31.4m | $202.4m |
| Loss per share | $0.19 | $1.25 |
Product sales almost doubled, but licensing and royalty income fell by a quarter as research reimbursements from Sanofi dropped by $42m. That support for Sanofi's post-approval commitments on Nuvaxovid is nearing its end. The year-earlier loss included a $97.0m impairment on assets held for sale and a $28.7m loss on paying off debt.
Over nine months, revenue fell to $264.5m from $976.3m, and Novavax swung to a net loss of $94.3m from net income of $422.8m.

The new guidance
2026 outlook, updated 5 November
- $385m to $415m adjusted total revenue, up from $235m to $275m
- $125m Sanofi combination vaccine milestone now included
- $375m to $395m combined R&D and SG&A spending
Besides the milestone, Novavax nudged up its forecasts for Nuvaxovid product sales to $40m to $50m, for supply sales to $50m to $60m, and for licensing, royalties and other income to $170m to $180m. The adjusted figures leave out commercial supply sold to Sanofi. Combined research and administrative spending is expected to be slightly lower than before.
An updated version of Nuvaxovid, matched to the XFG Covid variant, was approved in the US, the EU and Japan in August. Sanofi and Takeda, Novavax's partner in Japan, have started selling it for the 2026-2027 season, and Novavax is eligible for royalties on their sales.
Chief executive John Jacobs said that over time the partnership strategy could "build a robust and profitable Novavax".
Cash, debt and risks
Novavax ended September with $627m of cash, cash equivalents, marketable securities and restricted cash, down from $751m at the end of 2025. The $125m milestone was earned after the quarter closed. Long-term debt stood at $292.1m, and shareholders' equity was negative at $216.9m.
The company remains loss-making and depends heavily on Sanofi for future payments. A US launch of the combination vaccine, and the $225m that comes with it, depends on Sanofi completing US trials and approvals, which may need more studies than in other markets. Novavax also depends heavily on the Serum Institute of India for co-formulating, filling and finishing its Covid vaccine.
What to watch
- Fourth-quarter results, the first to include the $125m milestone
- The start of Sanofi's US Phase 3 combination trial, planned for 2027
- The $75m technology transfer milestone, expected in mid-2027
- Royalty income from Sanofi and Takeda over the 2026-2027 season
Sources
- Novavax (Form 8-K, Exhibit 99.1): Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights (2026-11-05)
- Novavax (Form 8-K, Exhibit 99.1): Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe (2026-10-29)
- U.S. Securities and Exchange Commission (EDGAR): Novavax, Inc. Form 10-Q for the quarter ended 30 September 2026 (2026-11-05)








